Showing 1091-1100 of 7029 results for "".
Dear Millennial Physician
https://practicaldermatology.com/topics/practice-management/dear-millennial-physician/20643/An established thought leader offers common sense and common courtesy concepts for each new generation of physicians.Smoothing Out Our Understanding of Moisturizers
https://practicaldermatology.com/topics/skin-cancer-photoprotection/smoothing-out-our-understanding-of-moisturizers/20688/New science and new approaches for dry skin.Expert Spotlight: Michael Werner
https://practicaldermatology.com/topics/practice-management/expert-spotlight-michael-werner/20722/Despite passage of the SIA, no new sunscreen ingredients have been approved in the US.Rafael Nunes, MD on LightSheer Duet and AcuPulse
https://practicaldermatology.com/topics/general-topics/rafael-nunes-md-on-lightsheer-duet-and-acupulse/19284/Journal Club: Updates in Topical Treatments for AD
https://practicaldermatology.com/series/practical-dermatology-journal-club-atopic-dermatitis/journal-club-updates-topical-treatments-ad/29744/Editorial Board member and dermatologist Dr. Peter Lio, talks with Dr. Ted Lain, a dermatologist at Sanova Dermatology, about the latest research and developments in topical treatments for AD. The discussion covers a range of therapies highlighted in an article from the Dermatologic Clinics articleDermWireTV: Atopic Dermatitis Pipeline Watch, a Potential New Skin Cancer Treatment; Demystifying Itch, and the Premiere of PA Perspectives
https://practicaldermatology.com/topics/practice-management/dermwiretv-atopic-dermatitis-pipeline-watch-a-potential-new-skin-cancer-treatment-demystifying-itch-and-the-premiere-of-pa-perspectives/20228/Escient Pharmaceuticals, Rapt Therapeutics, and Connect Biopharma each report positive results from early clinical studies in AD. Finnish researchers discover a potential treatment for cutaneous squamous cell carcinoma in an existing chemotherapy drug. Research out of Harvard Medical School links ecWhy We Should Be PRO Patients With CKD-Associated Pruritus
https://practicaldermatology.com/programs/cme/why-we-should-be-pro-patients-with-ckd-associated-pruritus/14968/Our experts offer tips to effectively use Patient-Reported Outcome Measures (PROMs) in clinical practice to improve health outcomes in patients with CKD-aP.KALMing the Itch: Improving QoL in Patients with CKD-aP
https://practicaldermatology.com/programs/cme/kalming-the-itch-improving-qol-in-patients-with-ckd-ap/14966/Join our experts to find ways to effectively manage your patients with CKD-aP and improve their quality of life using evidence-based approved therapy.Better Brow Lifts
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/better-brow-lifts/18302/An effective neuromodulator brow lift depends on identifying two key points that will help determine the ideal injection location, says Joel L. Cohen, MD, a dermatologist in Greenwood Village, CO. The key is to inject the orbicularis oculi only and to avoid the frontalis entirely. Dr. Cohen is co-edNot All PDE4 Inhibitors Are the Same
https://practicaldermatology.com/series/arcutis/not-all-pde4-inhibitors-are-the-same/24491/Phosphodiesterase 4 (PDE4) has been implicated in a wide range of inflammatory diseases, and is an established target in dermatology. However, not all PDE4 inhibitors are the same. Patrick Burnett, MD, PhD, FAAD, Chief Medical Officer at Arcutis, discusses the unique properties of topical roflumilas